Utah Medical Products (UTMD)
NASDAQ:UTMD
Want to see UTMD full AI Analyst Report?
Top Page
Utah Medical Products
(NASDAQ:UTMD)
Select Model
Select Model
Rating:72Outperform
Price Target:
$71.00
▲(27.54% Upside)
Action:Upgraded
Date:05/15/26
The score is driven primarily by strong financial quality—exceptionally conservative balance sheet, solid cash generation, and high margins—tempered by persistent revenue decline. Technical indicators are notably weak and weigh on the near-term outlook, while valuation and dividend are supportive but not compelling enough to offset the slowing top-line trend.
Positive Factors
Conservative balance sheet
Near-zero leverage and minimal debt versus a sizable equity base give the company durable financial flexibility. This conservatism lowers bankruptcy risk, supports capital allocation (buybacks, capex, M&A) and cushions shocks, strengthening resilience over the next 2–6 months and beyond.
Negative Factors
Persistent revenue decline
Multi-year top-line contraction erodes scale, limits operating leverage and constrains long-term growth options. Persistent revenue declines reduce ability to invest in new products or expand channels, increasing reliance on margin and cost control to sustain earnings over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Near-zero leverage and minimal debt versus a sizable equity base give the company durable financial flexibility. This conservatism lowers bankruptcy risk, supports capital allocation (buybacks, capex, M&A) and cushions shocks, strengthening resilience over the next 2–6 months and beyond.
Read all positive factors
Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$211.58M
Dividend Yield2.15%
Average Volume (3M)15.88K
Price to Earnings (P/E)19.5
Beta (1Y)0.60
Revenue Growth-4.43%
EPS Growth-10.66%
CountryUS
Employees155
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.30
Shares Outstanding3,184,025
10 Day Avg. Volume20,525
30 Day Avg. Volume15,884
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)1.55
Price to Sales (P/S)4.81
P/FCF Ratio12.93
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue3.31
Enterprise Value/Gross Profit6.18
Enterprise Value/Ebitda8.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Utah Medical Products Business Overview & Revenue Model
Company Description
Utah Medical Products, Inc. (UTMD) is a leading medical device company focused on developing and manufacturing high-quality medical products primarily for the healthcare sector. Founded in 1978 and headquartered in Midvale, Utah, the company speci...
How the Company Makes Money
UTMD makes money primarily by selling medical devices and related disposable products (single-use or repeat-purchase consumables) used in clinical procedures, with revenue recognized from product shipments to healthcare providers and distributors....
Utah Medical Products Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
95
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.53M | 38.52M | 40.90M | 50.22M | 52.28M | 49.05M |
| Gross Profit | 20.13M | 19.88M | 24.14M | 30.04M | 32.20M | 30.92M |
| EBITDA | 15.06M | 17.06M | 16.44M | 24.75M | 26.87M | 26.16M |
| Net Income | 10.85M | 11.29M | 13.87M | 16.64M | 16.47M | 14.79M |
Balance Sheet | ||||||
| Total Assets | 124.38M | 122.54M | 122.54M | 135.46M | 123.87M | 115.64M |
| Cash, Cash Equivalents and Short-Term Investments | 87.41M | 85.76M | 82.98M | 92.87M | 75.05M | 60.97M |
| Total Debt | 210.00K | 225.00K | 338.00K | 295.00K | 341.00K | 396.00K |
| Total Liabilities | 4.01M | 3.27M | 5.11M | 7.14M | 9.62M | 8.50M |
| Stockholders Equity | 120.37M | 119.27M | 117.43M | 128.31M | 114.25M | 107.14M |
Cash Flow | ||||||
| Free Cash Flow | 13.02M | 14.32M | 14.60M | 21.64M | 20.33M | 20.65M |
| Operating Cash Flow | 13.34M | 14.69M | 14.83M | 22.28M | 21.15M | 21.20M |
| Investing Cash Flow | -317.00K | -371.00K | -208.00K | -639.00K | -818.00K | -552.00K |
| Financing Cash Flow | -9.22M | -12.34M | -23.84M | -4.17M | -5.48M | -10.90M |
Utah Medical Products Technical Analysis
Positive
55.67
Price Trends
65.34
Positive
64.09
Positive
61.26
Positive
Market Momentum
<0.01
Negative
58.77
Neutral
76.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 55.67 is below the 20-day moving average (MA) of 64.72, below the 50-day MA of 65.34, and below the 200-day MA of 61.26, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.77 is Neutral, neither overbought nor oversold. The STOCH value of 76.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.
Utah Medical Products Risk Analysis
Utah Medical Products disclosed 10 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Utah Medical Products Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $211.58M | 19.51 | 9.13% | 2.15% | -4.43% | -10.66% | |
60 Neutral | $183.05M | 23.17 | 14.00% | ― | 3.50% | 157.81% | |
55 Neutral | $208.85M | -5.91 | -246.44% | ― | 17.41% | -189.91% | |
52 Neutral | $186.49M | -82.61 | -13.61% | ― | 23.30% | 57.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
UTMD
Utah Medical Products
66.45
12.84
23.96%
INFU
InfuSystem Holdings
9.07
3.39
59.68%
KRMD
REPRO-MED Systems
4.06
1.27
45.52%
SMTI
Sanara MedTech
22.79
-6.30
-21.66%
STSS
Sharps Technology, Inc.
1.83
-1.74
-48.74%
Utah Medical Products Corporate Events
Executive/Board ChangesShareholder Meetings
Utah Medical Shareholders Back Board, Auditor and Pay Policies
Positive
May 4, 2026
On May 1, 2026, Utah Medical Products stockholders voted on key governance and compensation matters at the company’s annual meeting, including the election of directors, ratification of the auditor, and an advisory say-on-pay resolution. Sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.